gip glp 1 reviews GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read LY3437943, a novel triple glucagon,

Rapid weight loss is a recognised risk factor for gallstone formation

The practice of microdosing GLP-1 receptor agonists is largely experimental and off-label

While the numbers we estimate are for Great Britain as a whole, it is noteworthy that the number using these medications for weight loss far exceeds the initial expectation for NHS England to provide treatment for 220,000 people in the first 3 years, which is likely to have important consequences for NHS budgets, although our estimate is less than the number eligible according to NICE guidelines (3.4 million) [14]

Dehydration, which can occur with gastrointestinal side effects such as vomiting or diarrhoea, may also contribute to joint discomfort

14 , e12495 (2019)